Genzyme kept by Merrill Lynch at neutral

Genzyme Inc. was maintained by Merrill Lynch analyst Eric Ende at a neutral rating due to valuation on the stock following new data on its Renagel drug, used to control phosphorus levels in patients on dialysis. Genzyme shares Thursday jumped $4.70, or 6.67%, to end the day at $75.20 on volume of 13,076,625 shares versus the three-month running average of 2,784,520 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.